Article

D. Ross Camidge on the Development of a New Lung Cancer Drug

Author(s):

D. Ross Camidge

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).

Camidge presented results from a study of brigatinib during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Related Content
Illustration of woman with blonde hair.
November 20th 2024

What Patients with Breast Cancer Need to Know About Lymphedema Risk

Alex Biese
CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with cancer are at risk for.
Image of woman with brown hair.
November 19th 2024

Newer Therapies for Acute Lymphoblastic Leukemia May Reduce Side Effects

Spencer Feldman Darlene Dobkowski, MA
New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.
Image of a woman with short blonde hair, wearing a colorful striped shirt.
November 19th 2024

Why Clinical Trials Don’t Have to Be Patients’ ‘Last Line of Defense’

Alex Biese
A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.
Image of bald man.
November 18th 2024

How Circulating Tumor Cell Count Can Inform Prostate Cancer Treatment

Alex Biese
An expert explained how circulating tumor cell count can identify possible clinical trial participants.
Image of woman with black hair.
November 12th 2024

Managing Trodelvy’s Side Effects Through Dose Adjustment

Spencer Feldman
An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose adjustments.
Picture of Dr. Guillermo Garcia-Manero
September 18th 2024

Why Transfusion Independence Matters for Patients With MDS

Alex Biese
An expert explained the burden that red blood cell transfusions can place on patients with MDS.